PNT / POINT Biopharma: Leading The Future Of Radioligand Therapy

On Tuesday, Eli Lilly agreed to acquire Point Biopharma for $12.50 per share in cash -- an 87% premium from Monday's close. The deal isn't subject to more_horizontal

Point Biopharma focuses on oncology therapies. The company's lead therapy is PNT2002 to treat prostate cancer. more_horizontal

Shares in Point Biopharma Global jumped 84% following the announcement that pharmaceutical giant Eli Lilly and Co (NYSE:LLY) will acquire the company more_horizontal

POINT Biopharma is a leader in radioligand therapy, specializing in the development and commercialization of targeted radioligand therapies for cancer more_horizontal

POINT Biopharma has two therapies in Phase 3 development with fast track designation, which creates the potential for positive catalysts as early as t more_horizontal

Point Biopharma Global released first-quarter earnings. The company said that its lead therapy had received fast-track designation from the FDA. more_horizontal

POINT Biopharma Global Inc. has a set of radioligand therapies in various stages. It has a major deal with Lantheus. more_horizontal

POINT Biopharma (PNT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal